Pivotal moments in HIV treatment: the 14th CROI.
Laurence
Jeffrey
J
D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced; D006801:Humans; D061466:Lopinavir; D000077592:Maraviroc; D015337:Multicenter Studies as Topic; D009930:Organic Chemicals / Q000009:adverse effects / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000009:adverse effects / Q000627:therapeutic use*; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
D044966:Anti-Retroviral Agents; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D009930:Organic Chemicals; D011744:Pyrimidinones; D011760:Pyrrolidinones; D014230:Triazoles; D061466:Lopinavir; D000068898:Raltegravir Potassium; D000077592:Maraviroc